• IDEAYA Biosciences dosed the first patient in OptimUM-11, a global Phase 3 registrational adjuvant trial in primary uveal melanoma.
• Results have not been presented; the study will assess whether the darovasertib-crizotinib regimen can delay or prevent metastatic recurrence.
• About 450 high-risk patients post-local therapy will be randomized to 12 months of treatment or observation, with relapse-free survival as primary endpoint.
• The program targets a market with no approved adjuvant systemic options in primary uveal melanoma, expanding darovasertib’s commercial opportunity.
• IDEAYA keeps US rights to darovasertib; Servier holds ex-US rights, with development costs for the Phase 3 trial shared.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609090600PR_NEWS_USPR_____SF42931) on September 09, 2026, and is solely responsible for the information contained therein.